TNXP

Tonix Pharmaceuticals Holding Corp. [TNXP] Stock Forecast

Buy or Sell ? Support and Resistance

What is MACD and how to read it?

How RSI can help?
RSI : 000

TNXP Stock Summary

Top 10 Correlated ETFs

TNXP


Top 10 Correlated Stocks

TNXP


In the News

07:00 08 Jun 2023 TNXP

Tonix Pharmaceuticals to Present at the June 1st Virtual Investor Summit

CHATHAM, N.J., May 24, 2023 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP), a clinical-stage biopharmaceutical company, announced today that Jessica Morris, Chief Operating Officer of Tonix Pharmaceuticals, will present at the June 1st Virtual Investor Summit on Thursday, June 1, 2023, at 10:30 a.m. ET.

04:41 08 Jun 2023 TNXP

Tonix Pharmaceuticals exec presents data on Prader-Willi Syndrome drug at rare disease conference

Tonix Pharmaceuticals (NASDAQ:TNXP) Holding Corp EVP of translation medicine Herbert Harris delivered an oral presentation Thursday at the Rare Disease Innovation and Partnership Summit in Philadelphia, the company announced.  The presentation, titled, “TNX-2900 (Intranasal Potentiated Oxytocin) in Development for the Treatment of Hyperphagia in Adolescents and Young Adults with Prader-Willi Syndrome,” includes data showing the enhancing effects of magnesium on the activation of oxytocin receptors.

07:00 08 Jun 2023 TNXP

Tonix Pharmaceuticals to Present at the 2023 Virtual March Investor Summit

CHATHAM, N.J., March 22, 2023 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP), a clinical-stage biopharmaceutical company, announced today that Jessica Morris, Chief Operating Officer of Tonix Pharmaceuticals, will present at the Virtual March Investor Summit on Wednesday, March 29, 2023, at 9:00 a.m. ET.

08:01 08 Jun 2023 TNXP

Tonix Pharmaceuticals obtains exclusive license to develop fully human and murine anti-SARS-CoV-2 monoclonal antibodies

Tonix Pharmaceuticals (NASDAQ:TNXP) Holding Corp. said it has exercised an option to obtain an exclusive license from Columbia University for the development of a portfolio of fully human (TNX-3600) and murine (TNX-4100) monoclonal antibodies (mAbs) for the treatment or prophylaxis of SARS-CoV-2 infection.  SARS-CoV-2 is the cause of COVID-19.

07:00 08 Jun 2023 TNXP

Tonix Pharmaceuticals to Participate in BIO CEO & Investor Conference

CHATHAM, N.J., Feb. 03, 2023 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (Tonix or the Company), a clinical-stage biopharmaceutical company, today announced that Seth Lederman, M.D., President and Chief Executive Officer of Tonix Pharmaceuticals, will participate virtually in the BIO CEO & Investor Conference, which is being held February 6-9, 2023.

06:00 08 Jun 2023 TNXP

Using News to Find Penny Stocks to Buy: 3 Tips

Are you using the news to find penny stocks to buy? The post Using News to Find Penny Stocks to Buy: 3 Tips appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

07:00 08 Jun 2023 TNXP

Tonix Pharmaceuticals to Present at Biotech Showcase 2023

CHATHAM, N.J., Jan. 03, 2023 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP), a clinical-stage biopharmaceutical company, announced today that Seth Lederman, M.D., Chief Executive Officer of Tonix Pharmaceuticals, will present at Biotech Showcase 2023 being held January 9-11, 2023, at the Hilton San Francisco Union Square.

06:00 08 Jun 2023 TNXP

How to Conduct Due Diligence on Penny Stocks, 3 Tips

Need help researching penny stocks to buy? Use these tips The post How to Conduct Due Diligence on Penny Stocks, 3 Tips appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

11:38 08 Jun 2023 TNXP

Why Is Tonix Pharmaceuticals (TNXP) Stock Up 40% Today?

Today is a banner day for anyone who happened to hold Tonix Pharmaceuticals (NASDAQ: TNXP ) stock over the weekend. Early this morning, Tonix disclosed an exclusive license with a drug developer which could produce an entirely new approach to treating Covid-19.

07:00 08 Jun 2023 TNXP

Tonix Pharmaceuticals to Present at the 2022 BioFuture Conference

CHATHAM, N.J., Oct. 31, 2022 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP), a clinical-stage biopharmaceutical company, announced today that Jessica Morris, Chief Operating Officer of Tonix Pharmaceuticals, will present at BioFuture on Tuesday, November 8, 2022, at 11:00 a.m. ET, and host investor meetings. The conference is being held at the Lotte New York Palace in New York City.

TNXP Financial details

Company Rating
Neutral
Market Cap
19.44M
Income
-119.82M
Revenue
18.77M
Book val./share
16.32
Cash/share
7.1
Dividend
-
Dividend %
-
Employees
117
Optionable
No
Shortable
Yes
Earnings
07 Aug 2023
P/E
-0.16
Forward P/E
-
PEG
0.05
P/S
1.05
P/B
0.12
P/C
0.26
P/FCF
-0.15
Quick Ratio
5.51
Current Ratio
6.4
Debt / Equity
0.08
LT Debt / Equity
0
-
-
EPS (TTM)
-5.39
EPS next Y
-
EPS next Q
-
EPS this Y
-60.25%
EPS next Y
-
EPS next 5Y
-
EPS last 5Y
-
Revenue last 5Y
-
Revenue Q/Q
-
EPS Q/Q
404.92%
-
-
-
-
SMA20
-
SMA50
-50%
SMA100
-71.43%
Inst Own
21.2%
Inst Trans
-0.83%
ROA
-67%
ROE
-58%
ROC
-0.72%
Gross Margin
281%
Oper. Margin
-637%
Profit Margin
-639%
Payout
-6%
Shs Outstand
10.34M
Shs Float
10.34M
-
-
-
-
Target Price
-
52W Range
1.62-17.9375
52W High
-88.94%
52W Low
+88%
RSI
40
Rel Volume
0.92
Avg Volume
217.23K
Volume
200.46K
Perf Week
0%
Perf Month
-37.33%
Perf Quarter
3.36%
Perf Half Y
-25.69%
-
-
-
-
Beta
2.18051
-
-
Volatility
0.04%, 0.48%
Prev Close
-1.57%
Price
1.88
Change
-3.59%

TNXP Financial Performance

Yearly Fundamentals Overview

Last date of statement is 2022-12-31

Metric History 2018-12-312019-12-312020-12-312021-12-31 2022-12-31
Revenue per share
00000
Net income per share
-238.29-3.53K-106.54-8.1-3.22
Operating cash flow per share
-218.94-3.32K-102.69-6.64-2.74
Free cash flow per share
-219-3.32K-120.79-9.74-4.09
Cash per share
228.651.4K162.9515.693.36
Book value per share
216.141.17K185.3219.215.8
Tangible book value per share
215.041.17K185.3219.215.8
Share holders equity per share
216.141.17K185.3219.215.8
Interest debt per share
044.522.770.08-0.2
Market cap
481.74M1.88M63.85M814.64M87.07M
Enterprise value
456.7M-9.01M-11.91M636.93M-32.4M
P/E ratio
-18.47-0.07-1.27-8.83-0.76
Price to sales ratio
00000
POCF ratio
-20.1-0.07-1.31-10.78-0.89
PFCF ratio
-20.09-0.07-1.12-7.35-0.6
P/B Ratio
20.360.20.733.720.42
PTB ratio
20.360.20.733.720.42
EV to sales
00000
Enterprise value over EBITDA
-17.540.310.24-6.90.29
EV to operating cash flow
-19.050.340.25-8.430.33
EV to free cash flow
-19.050.340.21-5.750.22
Earnings yield
-0.05-15.08-0.79-0.11-1.32
Free cash flow yield
-0.05-14.19-0.89-0.14-1.68
Debt to equity
0.110.550.120.10.09
Debt to assets
0.10.350.110.090.08
Net debt to EBITDA
0.960.381.51.931.07
Current ratio
9.812.728.968.717.19
Interest coverage
0001.85K14.17
Income quality
0.920.930.960.820.89
Dividend Yield
00000.08
Payout ratio
0000-0.06
Sales general and administrative to revenue
00000
Research and developement to revenue
00000
Intangibles to total assets
00.01000
Capex to operating cash flow
000.180.470.49
Capex to revenue
00000
Capex to depreciation
-0.11-0.65-317.19-706.14-38.43
Stock based compensation to revenue
00000
Graham number
1.08K9.64K666.559.1720.49
ROIC
1.052.60.830.715.12
Return on tangible assets
-1-1.97-0.51-0.38-0.51
Graham Net
208853.8152.7714.253.01
Working capital
23.4M8.81M78.17M167.33M112.6M
Tangible asset value
23.54M9.3M87.53M218.6M207.18M
Net current asset value
23.4M8.81M77.45M166.87M112.27M
Invested capital
00.040.0100
Average receivables
509.5K768K4.32M7.68M7.88M
Average payables
1.35M2.24M3.83M8.94M10.68M
Average inventory
00000
Days sales outstanding
00000
Days payables outstanding
00000
Days of inventory on hand
00000
Receivables turnover
00000
Payables turnover
00000
Inventory turnover
00000
ROE
-1.1-3.01-0.57-0.42-0.56
Capex per share
-0.05-2.11-18.11-3.1-1.35

Quarterly Fundamentals Overview

Last date of statement is 2023-03-31 for Q1

Metric History 2022-03-312022-06-302022-09-302022-12-31 2023-03-31
Revenue per share
00.40.2300
Net income per share
-1.62-1.02-0.68-0.61-3.08
Operating cash flow per share
-1.9-0.94-0.56-0.36-3.25
Free cash flow per share
-3.14-1.59-0.77-0.44-3.62
Cash per share
8.616.493.341.967.1
Book value per share
12.7510.195.463.3816.32
Tangible book value per share
12.7510.195.463.3816.32
Share holders equity per share
12.7510.195.463.3816.32
Interest debt per share
0.050.050.040-0.08
Market cap
751.14M221.24M140.04M149.53M37.45M
Enterprise value
611.51M76.75M951.59K30.06M-33.5M
P/E ratio
-7.11-2.41-1.23-1-0.3
Price to sales ratio
024.5114.3800
POCF ratio
-24.19-10.45-5.95-6.71-1.14
PFCF ratio
-14.65-6.21-4.33-5.54-1.02
P/B Ratio
3.610.970.610.720.23
PTB ratio
3.610.970.610.720.23
EV to sales
08.50.100
Enterprise value over EBITDA
-23.13-3.29-0.03-0.920.99
EV to operating cash flow
-19.7-3.63-0.04-1.351.02
EV to free cash flow
-11.93-2.16-0.03-1.110.91
Earnings yield
-0.04-0.1-0.2-0.25-0.83
Free cash flow yield
-0.07-0.16-0.23-0.18-0.98
Debt to equity
0.080.210.060.090.08
Debt to assets
0.070.170.060.080.08
Net debt to EBITDA
5.286.194.743.652.09
Current ratio
9.9612.0511.337.196.4
Interest coverage
-1.39K-119.06-48.5139.6718.94
Income quality
1.180.910.810.71
Dividend Yield
00.0200.020
Payout ratio
0-0.190-0.060
Sales general and administrative to revenue
00.750.7600
Research and developement to revenue
01.842.2800
Intangibles to total assets
00000
Capex to operating cash flow
0.650.680.370.210.12
Capex to revenue
0-1.6-0.9100
Capex to depreciation
-320.9-141.56-35-5.59-4.25
Stock based compensation to revenue
00.310.2800
Graham number
21.5415.329.116.7933.63
ROIC
0.40.950.691.69-1.18
Return on tangible assets
-0.12-0.08-0.12-0.17-0.17
Graham Net
7.644.363.011.765.75
Working capital
137.64M175.84M137.8M112.6M70.65M
Tangible asset value
207.96M228.28M228.92M207.18M165.43M
Net current asset value
137.23M143.86M137.42M112.27M70.07M
Invested capital
00000.01
Average receivables
3.86M004.02M4.02M
Average payables
11.34M9.48M7.06M6.31M8.04M
Average inventory
00000
Days sales outstanding
00000
Days payables outstanding
0000-21.28
Days of inventory on hand
00000
Receivables turnover
00000
Payables turnover
0000-4.23
Inventory turnover
00000
ROE
-0.13-0.1-0.12-0.18-0.19
Capex per share
-1.24-0.64-0.21-0.08-0.37

TNXP Frequently Asked Questions

What is Tonix Pharmaceuticals Holding Corp. stock symbol ?

Tonix Pharmaceuticals Holding Corp. is a US stock , located in Chatham of Nj and trading under the symbol TNXP

What is Tonix Pharmaceuticals Holding Corp. stock quote today ?

Tonix Pharmaceuticals Holding Corp. stock price is $1.88 today.

Is Tonix Pharmaceuticals Holding Corp. stock public?

Yes, Tonix Pharmaceuticals Holding Corp. is a publicly traded company.

Something similar

Top by Market Cap
Top Correlated ETFs
Top Correlated Stocks
Similar Market Cap